
Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
Agenus Inc. a leader in immuno-oncology innovation, announced new findings from a long-term survivor analysis of its Phase 1b C-800-01 trial evaluating botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, in heavily pretreated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The results were presented in a poster by Thomas U. Marron, MD, PhD, of the Tisch Cancer Center at Mount Sinai, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting in Phoenix, Arizona.
For patients with MSS mCRC whose cancer has progressed despite multiple treatments, treatment options remain limited, even among patients without active liver metastases. Historical studies of available later-line treatment regimens have reported median overall survival of approximately 10–14 months in relevant populations.1,2 Because survival beyond 18 months remains uncommon in this setting, the analysis defined long-term survivors as patients who lived at least 18 months after starting BOT+BAL.
The new SITC analysis builds on previously reported results from the full 123-patient cohort, which demonstrated median overall survival of 21.2 months and a 33% estimated three-year survival rate, as presented at ESMO GI 2026 and published in Clinical Cancer Research. The current post-hoc analysis takes a closer look at the patients who achieved long-term survival, examining their clinical characteristics, the durability of their responses and factors that may help explain their outcomes.
The analysis found that 51% (63/123) of patients survived at least 18 months after starting BOT+BAL, including patients who had received prior immunotherapy and undergone several rounds of different treatment. Among the 63 long-term survivors, median overall survival had not been reached and an estimated 59% were alive at three years.
For patients with metastatic MSS colorectal cancer without active liver metastases who have exhausted multiple therapies, living another year and a half or more is rare,” said Thomas U. Marron, MD, PhD, of the Tisch Cancer Center at Mount Sinai and presenting author of the study. “What is particularly interesting is that the long-term survivors did not fit a single favorable clinical profile. Durable benefit was seen even in patients previously treated with immunotherapy, and a subset remains alive without any further cancer treatment. These findings suggest the potential to meaningfully change the course of disease and provide a compelling rationale for evaluating this approach earlier in treatment.
Clinical Characteristics and Outcomes of Long-Term Survivors
This post hoc analysis compared patients who survived at least 18 months after initiating BOT+BAL (n=63) with those who survived less than 18 months (n=60).
- Broad patient characteristics: The two groups were generally similar across the characteristics examined including performance status, previous immunotherapy treatment, metastatic disease characteristics and several prognostic biomarkers.
- Durable responses: Among long-term survivors, 35% (22/63) had a confirmed tumor response, including three complete responses in which tumors disappeared. Median duration of response was not reached, with responses lasting at least 37.4 months and 10 ongoing at the time of reporting. Patients in both the full cohort and long-term survivor group received a median of two BOT doses.
- Time off treatment: Approximately 24% (15/63), or one in four long-term survivors, were alive and off all anticancer treatment at time of last follow-up. Of these patients, 13 had achieved tumor responses with BOT+BAL.
- Prior treatment exposure: Long-term survivors were less likely to have received three or more prior lines of treatment, 56% (35/63) compared with 78% (47/60) of shorter-term survivors.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.
Agenus’ Commitment to Patient Access
Agenus is committed to expanding patient access to BOT+BAL through regulatory approvals, clinical trials and authorized early-access pathways. Following the first marketing authorizations for Botvymo® (botensilimab) and Evamplix® (balstilimab) in Armenia for eligible adults with microsatellite stable (MSS) metastatic colorectal cancer without active liver metastases who have previously received available standard therapies, BOT+BAL remains investigational outside Armenia and is not approved by the U.S. Food and Drug Administration (FDA).
In France, the national Autorisation d’Accès Compassionnel (AAC) program provides fully reimbursed, hospital-based access to BOT+BAL for eligible patients with MSS metastatic colorectal cancer without active liver metastases, platinum-resistant or platinum-refractory ovarian cancer, and certain advanced soft-tissue sarcomas. In a growing number of other countries, BOT+BAL is available through physician-initiated named-patient programs under local regulations. BAP Pharma serves as Agenus’ global partner for the French AAC pathway and named-patient access programs.
About Botensilimab (BOT)
Botensilimab (BOT) is a human multifunctional, Fc-enhanced anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. BOT augments immune responses across a wide range of tumor types by priming and activating T cells, reducing intratumoral regulatory T cells, activating myeloid cells and inducing durable memory responses.
About Balstilimab (BAL)
Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in more than 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.









